Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia

BMC Medicine

Volumn 11, Issue 1, 2013, Pages

  Liu, Linda Y ^a   Yang, Ting ^a   Ji, Jun ^a   Wen, Qiaojun ^a   Morgan, Alexander A ^a   Jin, Bo ^a   Chen, Gongxing ^a   Lyell, Deirdre J ^a   Stevenson, David K ^a   Ling, Xuefeng B ^a   Butte, Atul J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

2D gel (two dimensional gel electrophoresis); LCMS; Multiplex analysis; Preeclampsia; Proteomic profile

Indexed keywords

FARNESOID X RECEPTOR; GROWTH HORMONE; HEME; HEMOGLOBIN; LIVER X RECEPTOR; NITRIC OXIDE; PHOSPHATIDYLETHANOLAMINE; PLACENTAL GROWTH FACTOR; PROTEOME; REACTIVE OXYGEN METABOLITE; REELIN; RETINOID X RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; EDEMA; FEMALE; GENETIC ALGORITHM; GESTATIONAL AGE; HEADACHE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PREECLAMPSIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEINURIA; PROTEOMICS; SEROLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MASS SPECTROMETRY; PRE-ECLAMPSIA; PREGNANCY; SEROLOGIC TESTS; SERUM; YOUNG ADULT;

EID: 84888175721     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-11-236     Document Type: Article

References (53)

1. Berg CJ, Mackay AP, Qin C, Callaghan WM. Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol 2009, 113:1075-1081.
2. MacKay AP, Berg CJ, Atrash HK, R A. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001, 97:533-538. 10.1016/S0029-7844(00)01223-0, 11275024.
3. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123:2856-2869. 10.1161/CIRCULATIONAHA.109.853127, 3148781, 21690502.
4. Gynecologists ACoOa ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002, 99:159-167. 10.1016/S0029-7844(01)01747-1, 16175681, Gynecologists ACoOa.
5. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol 2001, 97:261-267. 10.1016/S0029-7844(00)01125-X, 11165592.
6. Lapaire O, Grill S, Lalevee S, Kolla V, Hosli I, Hahn S. Microarray screening for novel preeclampsia biomarker candidates. Fetal Diagn Ther 2012, 31:147-153. 10.1159/000337325, 22472943.
7. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. Microarray analysis of differentially expressed fetal genes in placenta tissue derived from early and late onset severe preeclampsia. Placenta 2007, 28:487-497. 10.1016/j.placenta.2006.05.010, 16860862.
8. Loset M, Mundal SB, Johnson MP, Fenstad MH, Freed KA, Lian IA, Eide IP, Bjorge L, Blangero J, Moses EK. A transcriptional profile of the decidua in preeclampsia. Am J Obstet Gynecol 2011, 204:84. e81-27, 3011026, 20934677.
9. Johansson A, Loset M, Mundal SB, Johnson MP, Freed KA, Fenstad MH, Moses EK, Austgulen R, Blangero J. Partial correlation network analyses to detect altered gene interactions in human disease: using preeclampsia as a model. Hum Genet 2011, 129:25-34. 10.1007/s00439-010-0893-5, 3332147, 20931231.
10. Sitras V, Paulssen RH, Gronaas H, Leirvik J, Hanssen TA, Vartun A, Acharya G. Differential placental gene expression in severe preeclampsia. Placenta 2009, 30:424-433. 10.1016/j.placenta.2009.01.012, 19249095.
11. Tsai S, Hardison NE, James AH, Motsinger-Reif AA, Bischoff SR, Thames BH, Piedrahita JA. Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. Placenta 2011, 32:175-182. 10.1016/j.placenta.2010.11.014, 3039036, 21183218.
12. Winn VD, Gormley M, Paquet AC, Kjaer-Sorensen K, Kramer A, Rumer KK, Haimov-Kochman R, Yeh RF, Overgaard MT, Varki A, Oxvig C, Fisher SJ. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 2009, 150:452-462. 2630905, 18818296.
13. Kolla V, Jeno P, Moes S, Lapaire O, Hoesli I, Hahn S. Quantitative proteomic (iTRAQ) analysis of 1st trimester maternal plasma samples in pregnancies at risk for preeclampsia. J Biomed Biotechnol 2012, 2012:305964. 3335425, 22570525.
14. Mary S, Patil GV, Kulkarni AV, Kulkarni MJ, Joshi SR, Mehendale SS, Giri AP. Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery. Proteomics Clin Applications 2012, 6:79-90.
15. Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, McCulloch JW, Roberts CT, North RA, Chappell LC, Mischak H, Poston L, Dominiczak AF, Delles C. Urinary proteomics for prediction of preeclampsia. Hypertension 2011, 57:561-569. 10.1161/HYPERTENSIONAHA.110.164285, 21199994.
16. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, Ness RB, Roberts JM, Hubel CA. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005, 90:4895-4903. 10.1210/jc.2004-1955, 15886253.
17. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111:649-658. 151901, 12618519.
18. Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL, Karumanchi SA, Thadhani R. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005, 193:16-22. 10.1016/j.ajog.2005.03.016, 16021053.
19. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, Wolf M, Harger G, Markovic N. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005, 26:563-573. 10.1016/j.placenta.2004.09.001, 15993706.
20. Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003, 105:158-164. 10.1002/ijc.11059, 12673673.
21. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001, 184:1267-1272. 10.1067/mob.2001.113129, 11349200.
22. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998, 179:1539-1544. 10.1016/S0002-9378(98)70021-3, 9855593.
23. Stepan H, Schaarschmidt W, Jank A, Verlohren S, Kratzsch J. [Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience]. Z Geburtshilfe Neonatol 2010, 214:234-238. 10.1055/s-0030-1262827, 21207323.
24. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010, 202:161. e1-161. 11.
25. Morgan AA, Khatri P, Jones RH, Sarwal MM, Butte AJ. Comparison of multiplex meta analysis techniques for understanding the acute rejection of solid organ transplants. BMC Bioinform 2010, 11:S6.
26. Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Computational Biol 2010, 6.
27. Ling XB, Park JL, Carroll T, Nguyen KD, Lau K, Macaubas C, Chen E, Lee T, Sandborg C, Milojevic D, Kanegaye JT, Gao S, Burns J, Schilling J, Mellins ED. Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications. Proteomics 2010, 10:4415-4430. 10.1002/pmic.201000298, 3517169, 21136595.
28. Founds SA, Conley YP, Lyons-Weiler JF, Jeyabalan A, Hogge WA, Conrad KP. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009, 30:15-24. 2667803, 19027158.
29. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, Udagawa Y. Comparative gene expression profiing of placentas from patients with severe preeclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011, 9:107. 10.1186/1477-7827-9-107, 3199758, 21810232.
30. Dudley JT, Butte AJ. Identification of discriminating biomarkers for human disease using integrative network biology. Pac Symp Biocomput 2009, 27-38.
31. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004, 3:311-326. 10.1074/mcp.M300127-MCP200, 14718574.
32. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, Kapp EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik YK, Yoo JS, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X. Overview of the HUPO plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245. 10.1002/pmic.200500358, 16104056.
33. Zhang Y, Zhang Y, Adachi J, Olsen JV, Shi R, de Souza G, Pasini E, Foster LJ, Macek B, Zougman A, Kumar C, Wisniewski JR, Jun W, Mann M. MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes. Nucleic Acids Res 2007, 35:D771-D779. 10.1093/nar/gkl784, 1781136, 17090601.
34. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 2004, 101:13368-13373. 10.1073/pnas.0403453101, 516573, 15326289.
35. Efron B, Tibshirani R, Storey J, Tusher V. Empirical bayes analysis of microarray experiment. J Am Stat Assoc 2001, 96:1151-1160.
36. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
37. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941. 10.1093/bioinformatics/bti623, 16096348.
38. Griffin TJ, Gygi SP, Ideker T, Rist B, Eng J, Hood L, Aebersold R. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002, 1:323-333. 10.1074/mcp.M200001-MCP200, 12096114.
39. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, Bumgarner R, Goodlett DR, Aebersold R, Hood L. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001, 292:929-934. 10.1126/science.292.5518.929, 11340206.
40. Baliga NS, Pan M, Goo YA, Yi EC, Goodlett DR, Dimitrov K, Shannon P, Aebersold R, Ng WV, Hood L. Coordinate regulation of energy transduction modules in Halobacterium sp. analyzed by a global systems approach. Proc Natl Acad Sci USA 2002, 99:14913-14918. 10.1073/pnas.192558999, 137519, 12403819.
41. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-313. 10.1074/mcp.M200008-MCP200, 12096112.
42. Gibson DS, Blelock S, Curry J, Finnegan S, Healy A, Scaife C, McAllister C, Pennington S, Dunn M, Rooney M. Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis-proteomic patterns of joint inflammation in early stage disease. J Proteomics 2009, 72:656-676. 10.1016/j.jprot.2009.01.022, 19367684.
43. Anderson N. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
44. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003, 2:1096-1103. 10.1074/mcp.M300031-MCP200, 12917320.
45. Weedon-Fekjaer MS, Johnsen GM, Anthonisen EH, Sugulle M, Nebb HI, Duttaroy AK, Staff AC. Expression of liver X receptors in pregnancies complicated by preeclampsia. Placenta 2010, 31:818-824. 10.1016/j.placenta.2010.06.015, 20655109.
46. Bachmayer N, Rafik Hamad R, Liszka L, Bremme K, Sverremark-Ekstrom E. Aberrant uterine natural killer (NK)-cell expression and altered placental and serum levels of the NK-cell promoting cytokine interleukin-12 in pre-eclampsia. Am J Reprod Immunol 2006, 56:292-301. 10.1111/j.1600-0897.2006.00429.x, 17076673.
47. Daniel Y, Kupferminc MJ, Baram A, Jaffa AJ, Fait G, Wolman I, Lessing JB. Plasma interleukin-12 is elevated in patients with preeclampsia. Am J Reprod Immunol 1998, 39:376-380. 10.1111/j.1600-0897.1998.tb00372.x, 9645268.
48. Sakai M, Shiozaki A, Sasaki Y, Yoneda S, Saito S. The ratio of interleukin (IL)-18 to IL-12 secreted by peripheral blood mononuclear cells is increased in normal pregnant subjects and decreased in pre-eclamptic patients. J Reprod Immunol 2004, 61:133-143. 10.1016/j.jri.2004.01.001, 15063636.
49. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, Verlohren S. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 2013, doi: 10.1515/jpm-2013-0074.
50. Daponte A, Pournaras S, Polyzos NP, Tsezou A, Skentou H, Anastasiadou F, Lialios G, Messinis IE. Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum placental growth factor (PlGF) as biomarkers for ectopic pregnancy and missed abortion. J Clin Endocrinol Metab 2011, 96:E1444-1451. 10.1210/jc.2011-0037, 21715541.
51. Ganzevoort W, Rep A, de Vries JI, Bonsel GJ, Wolf H. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006, 195:495-503. 10.1016/j.ajog.2006.02.012, 16643825.
52. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?. Am J Obstet Gynecol 2000, 182:589-594. 10.1067/mob.2000.103890, 10739512.
53. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125:911-919. 10.1161/CIRCULATIONAHA.111.054361, 3319742, 22261192.